Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer

Supporting evidence

• Evaluation report

• Final appraisal determination committee papers  (PDF 332 KB)

  Published:

  13 May 2020

• Appraisal consultation committee papers (PDF 6.46 MB)

  Published:

  13 May 2020